MicroRNA as New Tools for Prostate Cancer Risk Assessment and Therapeutic Intervention: Results from Clinical Data Set and Patients’ Samples

Table 4

MicroRNAs associated with PCa therapy.

References	Sample type	Therapy	miRs deregulated	miRs selected as candidates
Josson et al. (2008) [107]	LnCaP and; LnCaP C4-2B	Radiation therapy	6 downregulated	miR-521	↓
Huang et al. (2013) [110]	PC3 radiation; resistant cells	Radiation therapy	1 upregulated	miR-95	↑
Ribas et al. (2009) [85]	LNCaP and LAPC-4	Hormone therapy	Overexpressed	miR-21	↑
Ottman et al. (2014) [113]	LnCap CDX; sensitive cells; LnCap CDX; non-sensitive cells	Androgen deprivation-therapy and casodex	21 upregulated; 22 downregulated	http://www.molecularcancer.com; /content/13/1/1
Lehmusvaara et al. (2013) [114]	28 tumor tissues ( goserelin-treated patients bicalutamide-treated patients no treated-patients)	Endocrine treatment	10 deregulated	miR-9 and miR-17	↑
				miR-218	↓
Zhang et al. (2011) [88]	Serum samples from localized PCa (), ADPC (), CRPC DTX treated () and BPH ()	Docetaxel	1 upregulated	miR-21 (in CRPC docetaxel resistant)	↑
Puhr et al. (2012) [116]	PC3 docetaxel-resistant cells	Docetaxel	2 downregulated	miR-200c, miR-205	↓
Lin et al. (2014) [118]	Serum and plasma samples from CRPC PCa () before and after therapy	Docetaxel	46 deregulated	miR-200c, miR-200b, miR-146a,
				miR-222, miR-301b, miR-20a
Kojima et al. (2010) [119]	PC3 paclitaxel-resistant cells	Paclitaxel	1 downregulated	miR-34a	↓
Fujita et al. (2010) [121]	PC3 and DU145	Paclitaxel	1 downregulated	miR-148	↓

PCa: prostate cancer; ADPC: androgen dependent prostate cancer; CRPC: castration resistant prostate cancer; BPH: benign prostatic hyperplasia; DTX: docetaxel; CDX: casodex.